To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

Mortality and cardiovascu… - University of Gothenburg, Sweden Till startsida
Sitemap
To content Read more about how we use cookies on gu.se

Contact form








 


Note! If you want an answer on a question you must specify your email address




Mortality and cardiovascular and respiratory morbidity in individuals with impaired FEV 1 (PURE): an international, community-based cohort study

Journal article
Authors M. Duong
S. Islam
S. Rangarajan
D. Leong
O. Kurmi
K. Teo
K. Killian
G. Dagenais
S. Lear
A. Wielgosz
S. Nair
V. Mohan
P. Mony
R. Gupta
R. Kumar
O. Rahman
K. Yusoff
J. L. du Plessis
E. U. Igumbor
J. Chifamba
W. Li
Y. Lu
F. Zhi
R. Yan
R. Iqbal
N. Ismail
K. Zatonska
K. Karsidag
Annika Rosengren
A. Bahonar
A. Yusufali
P. M. Lamelas
A. Avezum
P. Lopez-Jaramillo
F. Lanas
P. M. O'Byrne
S. Yusuf
Published in The Lancet Global Health
Volume 7
Issue 5
Pages e613-e623
ISSN 2214-109X
Publication year 2019
Published at Institute of Medicine, Department of Molecular and Clinical Medicine
Pages e613-e623
Language en
Links dx.doi.org/10.1016/S2214-109X(19)30...
Keywords fuel, adult, alcohol consumption, anthropometry, Article, asthma, body mass, cardiopulmonary insufficiency, cardiovascular disease, cerebrovascular accident, Chagas disease, chronic obstructive lung disease, cohort analysis, congestive heart failure, country economic status, diabetes mellitus, disease assessment, dose response, educational status, female, follow up, forced expiratory volume, forced vital capacity, grip strength, heart infarction, human, Human immunodeficiency virus infection, hypertension, incidence, lung function test, major clinical study, malaria, male, middle aged, morbidity, mortality, neoplasm, outcome assessment, pneumonia, predictive value, prevalence, priority journal, prospective study, questionnaire, respiratory tract disease, risk factor, spirometry, sudden death, systolic blood pressure, tobacco use, tuberculosis
Subject categories Public Health, Global Health, Social Medicine and Epidemiology

Abstract

Background: The associations between the extent of forced expiratory volume in 1 s (FEV 1 ) impairment and mortality, incident cardiovascular disease, and respiratory hospitalisations are unclear, and how these associations might vary across populations is unknown. Methods: In this international, community-based cohort study, we prospectively enrolled adults aged 35–70 years who had no intention of moving residences for 4 years from rural and urban communities across 17 countries. A portable spirometer was used to assess FEV 1 . FEV 1 values were standardised within countries for height, age, and sex, and expressed as a percentage of the country-specific predicted FEV 1 value (FEV 1 %). FEV 1 % was categorised as no impairment (FEV 1 % ≥0 SD from country-specific mean), mild impairment (FEV 1 % <0 SD to −1 SD), moderate impairment (FEV 1 % <–1 SD to −2 SDs), and severe impairment (FEV 1 % <–2 SDs [ie, clinically abnormal range]). Follow-up was done every 3 years to collect information on mortality, cardiovascular disease outcomes (including myocardial infarction, stroke, sudden death, or congestive heart failure), and respiratory hospitalisations (from chronic obstructive pulmonary disease, asthma, pneumonia, tuberculosis, or other pulmonary conditions). Fully adjusted hazard ratios (HRs) were calculated by multilevel Cox regression. Findings: Among 126 359 adults with acceptable spirometry data available, during a median 7·8 years (IQR 5·6–9·5) of follow-up, 5488 (4·3%) deaths, 5734 (4·5%) cardiovascular disease events, and 1948 (1·5%) respiratory hospitalisation events occurred. Relative to the no impairment group, mild to severe FEV 1 % impairments were associated with graded increases in mortality (HR 1·27 [95% CI 1·18–1·36] for mild, 1·74 [1·60–1·90] for moderate, and 2·54 [2·26–2·86] for severe impairment), cardiovascular disease (1·18 [1·10–1·26], 1·39 [1·28–1·51], 2·02 [1·75–2·32]), and respiratory hospitalisation (1·39 [1·24–1·56], 2·02 [1·75–2·32], 2·97 [2·45–3·60]), and this pattern persisted in subgroup analyses considering country income level and various baseline risk factors. Population-attributable risk for mortality (adjusted for age, sex, and country income) from mildly to moderately reduced FEV 1 % (24·7% [22·2–27·2]) was larger than that from severely reduced FEV 1 % (3·7% [2·1–5·2]) and from tobacco use (19·7% [17·2–22·3]), previous cardiovascular disease (5·5% [4·5–6·5]), and hypertension (17·1% [14·6–19·6]). Population-attributable risk for cardiovascular disease from mildly to moderately reduced FEV 1 was 17·3% (14·8–19·7), second only to the contribution of hypertension (30·1% [27·6–32·5]). Interpretation: FEV 1 is an independent and generalisable predictor of mortality, cardiovascular disease, and respiratory hospitalisation, even across the clinically normal range (mild to moderate impairment). Funding: Population Health Research Institute, the Canadian Institutes of Health Research, Heart and Stroke Foundation of Ontario, Ontario Ministry of Health and Long-Term Care, AstraZeneca, Sanofi-Aventis, Boehringer Ingelheim, Servier, and GlaxoSmithKline, Novartis, and King Pharma. Additional funders are listed in the appendix. © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license

Page Manager: Webmaster|Last update: 9/11/2012
Share:

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?